Microbiome therapies: a maturing movement
European Pharmaceutical Review
JUNE 27, 2023
Jeffrey Silber (JS): The most exciting news for the field over the past year has been FDA approval of the first two donor-derived microbiome-directed agents. For solid tumours, we are currently investigating the effect of MaaT013 in solid tumour (melanoma) in a Phase II trial sponsored by AP-HP.
103 
Let's personalize your content